Show simple item record

Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells

dc.contributor.authorLoney, Tania L.en_US
dc.contributor.authorParsels, Joshua D.en_US
dc.contributor.authorParsels, Leslie A.en_US
dc.contributor.authorRadany, Eric H.en_US
dc.contributor.authorMaybaum, Jonathanen_US
dc.contributor.authorWagner, Lois M.en_US
dc.date.accessioned2006-09-08T19:58:06Z
dc.date.available2006-09-08T19:58:06Z
dc.date.issued1998-09en_US
dc.identifier.citationParsels, Leslie A.; Parsels, Joshua D.; Wagner, Lois M.; Loney, Tania L.; Radany, Eric H.; Maybaum, Jonathan; (1998). "Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells." Cancer Chemotherapy and Pharmacology 42(5): 357-362. <http://hdl.handle.net/2027.42/42098>en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/42098
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9771948&dopt=citationen_US
dc.description.abstractPurpose : We have reported previously that the expression of E. coli dUTPase (dutE) can protect HT29 cells from 5-fluorodeoxyuridine (FdUrd)-induced DNA fragmentation and cytotoxicity. In the study reported here, we further characterized the ability of dutE expression in one HT29 clone, dutE7, to alter the effects of treatment with FdUrd and other thymidylate synthase (TS) inhibitors. In addition, we developed two HuTu80 dutE-expressing clones using a pLNCX-dutE retroviral construct and tested their sensitivity to FdUrd-induced DNA fragmentation and cytotoxicity. Methods : Both a dutE retroviral expression system and a dutE antibody were developed to facilitate the generation and screening of dutE-expressing clones. HT29 and HuTu80 clones expressing dutE were tested for drug-induced DNA damage with either alkaline elution or pulsed field gel electrophoresis and drug-induced loss of clonogenicity. Results : Following a 24-h treatment with 100 μ M CB3717 or 500 n M methotrexate (MTX), dutE7 cells were significantly less sensitive to drug-induced loss of clonogenicity than con3 cells. DutE7 cells were also resistant to CB3717-induced DNA fragmentation at 24 h. However, following a 48-h treatment with CB3717 or MTX there was no difference in survival between con3 and dutE7 cells, even though DNA damage was still greatly attenuated in the dutE7 cell line. In addition, expression of dutE in two HuTu80 clones, 80  C and 80  K, did not protect these cells from FdUrd-induced DNA damage or cytotoxicity. Conclusions : We conclude that the role of uracil misincorporation and subsequent DNA damage in cytotoxicity induced by TS inhibitors, in HT29 cells, is time dependent, and that cytotoxicity caused by long-term exposure to these drugs is largely independent of resultant DNA damage, in this cell line. The inability of dutE to protect HuTu80 cells from FdUrd further suggests that the significance of uracil misincorporation resulting from TS inhibition varies among cell lines.en_US
dc.format.extent284112 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlag; Springer-Verlag Berlin Heidelbergen_US
dc.subject.otherDNA Damageen_US
dc.subject.otherResistanceen_US
dc.subject.otherKey Words DUTPaseen_US
dc.subject.otherUracilen_US
dc.subject.otherLegacyen_US
dc.subject.otherThymidylate Synthaseen_US
dc.titleMechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cellsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-0504, USA, USen_US
dc.contributor.affiliationumDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109-0504, USA, USen_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-0504, USA, USen_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-0504, USA, USen_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-0504, USA, USen_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-0504, USA, USen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid9771948en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/42098/1/280-42-5-357_80420357.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s002800050829en_US
dc.identifier.sourceCancer Chemotherapy and Pharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.